BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-16

Study Completion Date

2015-02-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.

Phase I part The objective of the phase I part is to define the Maximum Tolerated Dose (MTD) of BIBF 1120 at a dose level up to twice daily 200 mg with standard dose of pemetrexed (500 mg/m\^2) and to determine the Recommended Dose (RD) for the phase II part.

Phase II, to investigate the efficacy and safety of BIBF 1120 in combination with pemetrexed (500 mg/m\^2) as compared to pemetrexed (500 mg/m\^2) + placebo

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

NCT02182102

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE1

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

NCT00876460

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE1

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE3

A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer

NCT02182232

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE1

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

NCT02211833

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BIBF 1120 BID + Pemetrexed

Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m\^2 pemetrexed once every 3 weeks

Group Type EXPERIMENTAL

BIBF 1120 M + Pemetrexed

Intervention Type DRUG

BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2

BIBF 1120 H + Pemetrexed

Intervention Type DRUG

BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2

BIBF 1120 L + Pemetrexed

Intervention Type DRUG

BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2

BIBF 1120 BID (RD) + Pemetrexed

PHase II part: Study arm

Group Type EXPERIMENTAL

BIBF 1120 RD + Pemetrexed

Intervention Type DRUG

confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2

BIBF 1120 BID(Placebo) + Pemetrexed

Phase II part: Comparator arm

Group Type EXPERIMENTAL

BIBF 1120 Placebo + Pemetrexed

Intervention Type DRUG

placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BIBF 1120 M + Pemetrexed

BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2

Intervention Type DRUG

BIBF 1120 H + Pemetrexed

BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2

Intervention Type DRUG

BIBF 1120 RD + Pemetrexed

confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2

Intervention Type DRUG

BIBF 1120 L + Pemetrexed

BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2

Intervention Type DRUG

BIBF 1120 Placebo + Pemetrexed

placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients of age \>=20 and \<=74 years at informed consent
2. Histologically or cytologically confirmed, Non Small Cell Lung Cancer (NSCLC) of stage IIIB or IV or recurrent NSCLC
3. Relapse or failure of 1 first-line prior chemotherapy
4. Life expectancy of at least 3 months
5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
6. Patients who have sufficient baseline organ function over 4 weeks and whose laboratory data meet the following criteria at the enrolment

* Haemoglobin \>=9.0 g/dL
* Absolute neutrophil count (ANC) \>=1500/mm\^3
* Platelet count \>=100 000/mm\^3
* Total bilirubin under the upper limit of normal
* AST/SGOT and/or ALT/GPT \<=1.5 x upper limit of normal (if related to liver metastases \<=2.5 x upper limit of normal also)
* Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less
* Calculated creatinine clearance by Cockcroft Gault \>=45 mL/min
* Prothrombin time-international normalized ratio (PT-INR) and/or partial thromboplastin time (PTT) greater than 50% deviation from normal limits
* arterial oxgen pressure (PaO2) \>=60 torr or oxygen saturation by pulse-oximeter SpO2 \>=92%
7. Patient has given written informed consent which must be consistent with ICH-GCP and local legislation.

Exclusion Criteria

1. Patients who have received treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with this trial or who have not recovered from side effects of such therapy (except for alopecia)
2. Patients who have received chemo-, hormone-, immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug or who have not recovered from side effects of such therapy (except for alopecia) .
3. Patients who have received radiotherapy within the following period Phase I part: the past 4 weeks prior to treatment with the trial drug (in case of palliative radiotherapy such as for extremities, within the past 2 weeks prior to treatment with the trial drug)
4. Previous therapy with other vascular endothelial growth factor receptor (VEGFR) inhibitors or vascular endothelial growth factor (VEGF) ligand inhibitors for treatment of NSCLC
5. Previous therapy with BIBF 1120 and/or pemetrexed for treatment of NSCLC and any contraindications for therapy with pemetrexed
6. Patients who have active brain metastases
7. Leptomeningeal disease
8. Patients with distinct or suspected pulmonary fibrosis or interstitial lung disease by the CT findings, or patients with a previous history of pulmonary fibrosis or interstitial lung disease (except irradiation-pneumonitis appearing radiation field with past radiotherapy).
9. Radiographic evidence of cavitary or necrotic tumors
10. Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels
11. History of clinically significant haemoptysis within the past 3 months
12. History of major thrombotic or clinically relevant major bleeding event in the past 6 months
13. Known inherited predisposition to bleeding or thrombosis
14. Significant cardiovascular diseases
15. Significant weight loss (\>10%) within the past 6 weeks prior to treatment in the present trial
16. Current peripheral neuropathy CTCAE grade 2 or greater except due to trauma
17. Pre-existing ascites and/or clinically significant pleural effusion
18. Major injuries and/or surgery within the past 4 weeks prior to randomisation with incomplete wound healing
19. Clinically serious infections
20. Decompensated diabetes mellitus
21. Contraindication to high dose steroid therapy
22. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
23. Patients who have active or chronic hepatitis C and/or B infection and diagnosis of human immunodeficiency virus (HIV) infection
24. Other malignancy other than basal cell skin cancer, carcinoma in situ or intra-mucosal cancer that were judged to be cured by adequate treatment and disease-free interval is more than 5 years
25. History of serious drug hypersensitivity
26. Serious illness or concomitant non-oncological disease such as neurologic-, psychiatric-, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation
27. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy
28. Patients who are sexually active and unwilling to use a medically acceptable method of contraception
29. Pregnancy or breast feeding
30. Active alcohol or drug abuse
31. Patients unable to comply with the protocol
32. Other patients judged ineligible for enrolment in the study by the investigator or subinvestigator.

Minimum Eligible Age

20 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No